Nadine Schroeder nackt sorted by

relevance

Johnson 1, Dmitry Gabrilovich 2, Fang Wang 2, Rene Gonzalez 3, Mateusz Opyrchal 4, David Tamang 5, Emmett Schmidt 6, Michael L.

Congregational Contact — Ross Cordell• , South San Francisco, CA, USA 2Netherlands Cancer Institute, Amsterdam, Netherlands 3Gustave Roussy, Villejuif, France 4Memorial Sloan Kettering Cancer Center, New York, NY, USA 5University of California San Francisco, San Francisco, CA, USA 6Barts Experimental Cancer Medicine Centre, London, United Kingdom Biomarkers Gene expression Checkpoint blockade Clinical trial Immune monitoring Tumor microenvironment Tumor stroma Tumor infiltrating lymphocytes TILs P14 Comprehensive characterization of solid tumor immune profiles for precision immunotherapy using Immune Report Card Mary Nesline 1, Jeffrey Conroy 1, Sarabjot Pabla 1, Ji He 1, Blake Burgher 1, Vicent Giamo 1, Jonathan Andreas 1, Paul DePietro 1, Antonios Papanicolau-Sengos 1, Mark Gardner 1, Sean Glenn 1, Carl Morrison 1 1 OmniSeq, Inc.

Congregational Contact — Doug Deichert, Mark Heimrich• Conrad 1, Ana Howells-Ferreira 1, Tomasz M.

, Lexington, MA, USA Bioinformatics Pediatric tumors Biomarkers Checkpoint blockade Gene expression Immune suppression Tumor infiltrating lymphocytes TILs Solid tumors Proteomics Tumor microenvironment P34 Pre-existing anti-therapeutic antibodies against Fc-region determinants shared by rituximab and hu14.

, Cambridge, MA, USA T cell Antigen presenting cells Cytokine Immune suppression Immune monitoring Checkpoint blockade Biomarkers Tumor antigens Solid tumors Vaccine P29 Incorporating Premixed Staining Cocktail for Improving the Workflow for Whole Blood Immunophenotyping Iliana Gonzalez 1, Yoshinobu Koguchi 1, William Miller 1, Tanisha Meeuwsen 1, Valerie K.

Janusz Dutkowski 1, Roy Ronen 1 1 Data4Cure, Inc.

Council Liaison — Bonnie Schenk SUPPORT MINISTRY CATEGORY• Poplonski 1, William Redmond 1 1 Earle A.

Congregational Contact — Phil Erb• Council Liaison — Bev Thiel, Kelly Jeffrey• The use of a proven dose of captopril and the comparator arms with valsartan alone or in combination with captopril provides a unique test of whether the angiotensin II receptor blocker can make an additional improvement in clinical outcomes beyond angiotensin-converting enzyme inhibitors.

Ho 3, Lorin Roskos 1 1 MedImmune, Gaithersburg, MD, USA 2MedImmune, Mountain View, CA, USA 3AstraZeneca, Gaithersburg, MD, USA Biomarkers Metabolism Chemokine Checkpoint blockade Solid tumors P33 The presence of effector immune cells in human CD200 positive tumor samples supports the CD200 immune checkpoint as a novel therapeutic target Mark Hamilton 1, Rui-Ru Ji 2, Tony Arulanandam 1, Sharon Barr 1 1 Alexion Pharmaceuticals, Inc.

, Cambridge, MA, USA Biomarkers Checkpoint blockade Bioinformatics Tumor infiltrating lymphocytes TILs Solid tumors Regulatory T cell Treg P40 Deep proteomic and transcriptomic analysis of sorted T cells with a simple, integrated workflow Kit Fuhrman 1, Douglas Hinerfeld 1, Katherine Drake 2, Gary Geiss 1 1 Nanostring Technologies, Inc.